Taiwan's National Health Insurance Administration (NHIA) has decided to cover an expensive but effective gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, sparking debate over fairness and treatment access for patients with other rare conditions.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Foreign player awarded NT$10 million in wrongful contract termination
06/24/2026 01:24 PM - Society
Clinic chain chief indicted for attempted rape amid privacy fight
06/24/2026 11:54 AM - Society
Taiwan headline news
06/24/2026 11:47 AM - Politics
China's Fujian aircraft carrier transits Taiwan Strait
06/24/2026 10:36 AM - Business
U.S. dollar up in Taipei trading
06/24/2026 10:31 AM